Clinical trials and equitable care pathways are needed to build on early evidence of benefit Substance use disorders (SUDs) are common and burdensome for patients, families, and health systems,12 yet ...

Since 2021, the story of GLP-1s has illustrated that scientific progress is rarely a straight line from hypothesis to patient ...

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

People struggling with many addictions, ranging from opioids to gambling, are reporting similar experiences in clinics, on social media and around dinner tables.